The Tumor Treating Fields Therapy Market is driven by Advancements in Cancer Treatment Modalities
![]() |
Tumor Treating Fields Therapy Market |
Tumor
treating fields therapy, also known as tumor treating fields (TTFields),
utilizes low intensity alternating electric fields to inhibit tumor growth and
induce cell death in cancer cells. TTFields disrupt mitosis, the process of
cell division, and have proven effective for glioblastoma, the most common and
aggressive form of primary brain cancer. The therapy works through placement of
transducer arrays on the skin of the patient, which deliver the low intensity
electrical field to the targeted tumor region through the principle of
dielectric polarization and force. Compared to chemotherapy which causes
systemic toxicity, TTFields offer localized treatment with minimal side
effects.
The
global Tumor Treating Fields Market is estimated to be valued at US$ 333.8
million in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast
period 2023 to 2030, as highlighted in a new report published by Coherent
Market Insights.
Market key trends:
One of the key trends in the tumor treating fields therapy market is growing
adoption rates, especially for the treatment of glioblastoma. According to
recent studies, TTFields adoption rates have increased from 25% of eligible
glioblastoma patients in 2013 to over 50% in 2020 in the United States. This is
attributed to clinical evidence demonstrating TTFields improves progression
free and overall survival compared to chemotherapy. Additionally, the therapy
has gained approvals for other cancer types including mesothelioma, brain
metastasis from non-small cell lung cancer and pancreatic cancer. This wider
label expansion is expected to further drive the revenues of tumor treating
fields therapy market over the forecast period.
Porter's Analysis
Threat of new entrants: Low barrier to entry as manufacturing and distribution
of tumor treating fields devices do not require large capital investment,
however existing players have established brand names and distribution
networks.
Bargaining power of buyers: Buyers have moderate bargaining power due to the
availability of treatment alternatives but the growing incidence of cancer is
increasing demand for tumor treating fields devices.
Bargaining power of suppliers: Suppliers have low to moderate bargaining power
as raw materials required are commodity chemicals however sustained
relationships and contractual agreements lessen this power.
Threat of new substitutes: Threat of substitutes is low as other treatment
options like chemotherapy, radiation therapy and surgery are used in
combination with tumor treating fields for effective treatment but have
limitations.
Competitive rivalry: High as the market is dominated by Tier 1 Company and few
other global companies investing heavily in innovation and customer service to
fight competition.
Key Takeaways
The Global
Tumor Treating Fields Market Share is expected to witness high growth.
The global Tumor Treating Fields Market is estimated to be valued at US$ 333.8
million in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast
period 2023 to 2030.
The
North America tumor treating fields market accounted for largest share in 2023
due to presence of advanced healthcare facilities, favorable reimbursement
policies, increasing healthcare spending and growing cancer incidence in the US
and Canada. The Asia Pacific market is estimated to grow at fastest CAGR from
2023 to 2030 owing to improving access to healthcare services, healthcare
reforms to provide universal coverage and rising medical tourism in countries
like China, India and Japan.
Key players operating in the tumor treating fields market are Tier 1 Company,
Company 2 and Company 3. Key players operating in the (incorporate given market
name) are Tier 1 Company, Company 2 and Company 3. Tier 1 Company leads the
global market and has strong brand presence worldwide. It continues to launch
innovative tumor treating fields devices like device name through extensive
R&D. Company 2 holds second position in terms of revenue and has wide
distribution network across Europe and Asia Pacific. Company 3 has strong
foothold in the US market and is expanding its manufacturing facilities to
cater rising demand from emerging countries.
For more insights, Read- https://www.insightprobing.com/tumor-treating-fields-market-size-and-share/
Comments
Post a Comment